American Journal of Obstetrics & Gynecology
Volume 201, Issue 5 , Pages 472.e1-472.e7 , November 2009

First-trimester maternal plasma cell-free fetal DNA and preeclampsia

  • Stavros Sifakis, MD

      Affiliations

    • Harris Birthright Research Center for Fetal Medicine, King's College Hospital, London, UK
    • Laboratory of Clinical Virology, Medical School, University of Crete, Heraklion, Greece
    • ,
  • Apostolos Zaravinos, PhD

      Affiliations

    • Laboratory of Clinical Virology, Medical School, University of Crete, Heraklion, Greece
    • ,
  • Nerea Maiz, MD

      Affiliations

    • Harris Birthright Research Center for Fetal Medicine, King's College Hospital, London, UK
    • ,
  • Demetrios A. Spandidos, PhD

      Affiliations

    • Laboratory of Clinical Virology, Medical School, University of Crete, Heraklion, Greece
    • ,
  • Kypros H. Nicolaides, MD

      Affiliations

    • Harris Birthright Research Center for Fetal Medicine, King's College Hospital, London, UK
    • Corresponding Author InformationReprints: Kypros H. Nicolaides, MD, Harris Birthright Research Center for Fetal Medicine, King's College Hospital, Denmark Hill, London SE5 9RS, UK

Received 21 January 2009 ,Revised 16 March 2009 ,Accepted 14 May 2009.

References 

  1. World Health Organization. Make every mother and child count: World Health Report, 2005. Geneva: World Health Organization; 2005;
  2. In:  Lewis G editors. Why mothers die 2000-2002: the sixth report of confidential enquiries into maternal deaths in the United Kingdom. London: RCOG Press; 2004;
  3. American College of Obstetricians and Gynecologists: Committee on Practice Bulletins—Obstetrics. Diagnosis and management of preeclampsia and eclampsia: ACOG practice bulletin no: 33. Obstet Gynecol. 2002;99:159–167
  4. Brosens I, Robertson WB, Dixon HG. The physiological response of the vessels of the placental bed to normal pregnancy. J Pathol Bacteriol. 1967;93:569–579
  5. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. BJOG. 1986;93:1049–1059
  6. Pijnenborg R, Anthony J, Davey DA, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. BJOG. 1991;98:648–655
  7. Plascencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;30:742–749
  8. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330:565–572
  9. Lo YM, Leung TN, Tein MS, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem. 1999;45:184–188
  10. Zhong XY, Laivuori H, Livingston JC, et al. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am J Obstet Gynecol. 2001;184:414–419
  11. Smid M, Vassallo A, Lagona F, et al. Quantitative analysis of fetal DNA in maternal plasma in pathological conditions associated with placental abnormalities. Ann N Y Acad Sci. 2001;945:132–137
  12. Swinkels DW, de Kok JB, Hendriks JC, Wiegerinck E, Zusterzeel PL, Steegers EA. Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome as a complication of preeclampsia in pregnant women increases the amount of cell-free fetal and maternal DNA in maternal plasma and serum. Clin Chem. 2002;48:650–653
  13. Lau TW, Leung TN, Chan LY, et al. Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clin Chem. 2002;48:2141–2146
  14. Sekizawa A, Jimbo M, Saito H, et al. Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction. Am J Obstet Gynecol. 2003;188:480–484
  15. Shimada K, Murakami K, Shozu M, Segawa T, Sumitani H, Inoue M. Sex-determining region Y levels in maternal plasma: evaluation in abnormal pregnancy. J Obstet Gynaecol Res. 2004;30:148–154
  16. Farina A, Sekizawa A, Rizzo N, et al. Cell-free fetal DNA (SRY locus) concentration in maternal plasma is directly correlated to the time elapsed from the onset of preeclampsia to the collection of blood. Prenat Diagn. 2004;24:293–297
  17. Zhong XY, Gebhardt S, Hillermann R, Tofa KC, Holzgreve W, Hahn S. Parallel assessment of circulatory fetal DNA and corticotropin-releasing hormone mRNA in early- and late-onset preeclampsia. Clin Chem. 2005;51:1730–1733
  18. Smid M, Galbiati S, Lojacono A, et al. Correlation of fetal DNA levels in maternal plasma with Doppler status in pathological pregnancies. Prenat Diagn. 2006;26:785–790
  19. Leung TN, Zhang J, Lau TK, Lo YM. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem. 2001;47:137–139
  20. Zhong XY, Holzgreve W, Hahn S. The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy. 2002;21:77–83
  21. Levine RJ, Qian C, Leshane ES, et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol. 2004;190:707–713
  22. Farina A, Sekizawa A, Sugito Y, et al. Fetal DNA in maternal plasma as a screening variable for preeclampsia: a preliminary nonparametric analysis of detection rate in low-risk nonsymptomatic patients. Prenat Diagn. 2004;24:83–86
  23. Crowley A, Martin C, Fitzpatrick P, et al. Free fetal DNA is not increased before 22 weeks in intrauterine growth restriction or pre-eclampsia. Prenat Diagn. 2007;27:174–179
  24. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation: Fetal Medicine Foundation First Trimester Screening Group. Lancet. 1998;352:343–346
  25. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal NT, free β hCG and PAPP-A. Ultrasound Obstet Gynecol. 2008;31:618–624
  26. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1988;158:892–898
  27. Sherrill CB, Marshall DJ, Moser MJ, et al. Nucleic acid analysis using an expanded genetic alphabet to quench fluorescence. J Am Chem Soc. 2004;126:4550–4556
  28. Johnson SC, Sherrill CB, Marshall DJ, Moser MJ, Prudent JR. A third base pair for the polymerase chain reaction: inserting isoC and isoG. Nucleic Acids Res. 2004;32:1937–1941
  29. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–310
  30. von Dadelszen P, Magee LA, Roberts JM. Subclassification of pre-eclampsia. Hypertens Pregnancy. 2003;22:143–148
  31. Witlin GA, Saade GR, Mattar FM, Sibai BM. Predictors of neonatal outcome in women with severe pre-eclampsia or eclampsia between 24 and 33 weeks' gestation. Am J Obstet Gynecol. 1999;1(suppl):S19
  32. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001;323:1213–1217
  33. Zimmermann B, El-Sheikhah A, Nicolaides K, Holzgreve W, Hahn S. Optimized real-time quantitative PCR measurement of male fetal DNA in maternal plasma. Clin Chem. 2005;51:1598–1604
  34. Picchiassi E, Coata G, Fanetti A, Centra M, Pennacchi L, Di Renzo GC. The best approach for early prediction of fetal gender by using free fetal DNA from maternal plasma. Prenat Diagn. 2008;28:525–530
  35. Holzgreve W, Ghezzi F, Di Naro E, Ganshirt D, Maymon E, Hahn S. Disturbed feto-maternal cell traffic in preeclampsia. Obstet Gynecol. 1998;91:669–672
  36. Knight M, Redman CW, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. BJOG. 1998;105:632–640
  37. Al-Mufti R, Hambley H, Albaiges G, Lees C, Nicolaides KH. Increased fetal erythroblasts in women who subsequently develop pre-eclampsia. Hum Reprod. 2000;15:1624–1628
  38. Holzgreve W, Li JC, Steinborn A, et al. Elevation in erythroblast count in maternal blood before the onset of preeclampsia. Am J Obstet Gynecol. 2001;184:165–168
  39. Akolekar R, Zaragoza E, Poon LCY, Pepes S, Nicolaides KH. Maternal serum placental growth factor (PlGF) at 11 + 0 to 13 + 6 weeks of gestation in the prediction of preeclampsia. Ultrasound Obstet Gynecol. 2008;32:732–739

 Cite this article as: Sifakis S, Zaravinos A, Maiz N, et al. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol 2009;201:472.e1-7.

 This study was supported by a Grant from the Fetal Medicine Foundation (UK Charity no. 1037116).

PII: S0002-9378(09)00533-X

doi: 10.1016/j.ajog.2009.05.025

American Journal of Obstetrics & Gynecology
Volume 201, Issue 5 , Pages 472.e1-472.e7 , November 2009

Article Tools

* Image Usage & Resolution